Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 197

Similar articles for PubMed (Select 17047046)

1.

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC.

Cancer Res. 2006 Oct 15;66(20):9852-61.

2.

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM.

J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94.

PMID:
17021403
3.

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB.

J Clin Oncol. 2000 Feb;18(3):636-45.

PMID:
10653879
5.

Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.

Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW.

Front Biosci. 2003 Jan 1;8:a1-9.

PMID:
12456321
6.

Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.

Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G.

Brain Pathol. 2004 Apr;14(2):121-30.

PMID:
15193024
8.

Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.

Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K.

Brain Pathol. 2008 Jul;18(3):360-9. doi: 10.1111/j.1750-3639.2008.00129.x. Epub 2008 Mar 26.

PMID:
18371182
9.

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M; GICNO.

J Clin Oncol. 2006 Oct 10;24(29):4746-53. Epub 2006 Sep 5.

10.
11.

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG.

Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30.

PMID:
11020580
12.

Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.

Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.

Chin Med J (Engl). 2010 Dec;123(24):3566-73.

PMID:
22166632
13.

The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.

Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, Stevens G, Peereboom D, Suh J, Lee SY, Tubbs RR, Barnett GH.

J Neurosurg. 2006 Apr;104(4):542-50.

PMID:
16619658
14.

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.

J Clin Oncol. 2006 Jun 20;24(18):2715-22.

16.

Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.

Gelpi E, Ambros IM, Birner P, Luegmayr A, Drlicek M, Fischer I, Kleinert R, Maier H, Huemer M, Gatterbauer B, Anton J, Rössler K, Budka H, Ambros PF, Hainfellner JA.

Mod Pathol. 2003 Jul;16(7):708-15.

17.

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A; German Glioma Network.

Clin Cancer Res. 2007 Dec 1;13(23):6933-7.

18.

Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?

Gadji M, Fortin D, Tsanaclis AM, Drouin R.

Cancer Genet Cytogenet. 2009 Oct;194(1):12-22. doi: 10.1016/j.cancergencyto.2009.05.004.

PMID:
19737649
19.

Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N.

J Neurooncol. 2011 May;102(3):443-9. doi: 10.1007/s11060-010-0340-4. Epub 2010 Aug 19.

PMID:
20721680
20.

Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.

Choi KY, Jung TY, Jung S, Kim YH, Moon KS, Kim IY, Kang SS, Lee KH.

J Neurooncol. 2011 May;103(1):103-10. doi: 10.1007/s11060-010-0353-z. Epub 2010 Aug 25.

PMID:
20737192
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk